Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.44 |
| ▸ | SIRT2 | Q8IXJ6 | 8/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 7/20 | 0.42 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.42 |
| ▸ | TLR2 | O60603 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5550454 | 1.00 | KMT2A (0.46) | KMT2ASIRT5SIRT2SIRT1SIRT3 | |
| SCHEMBL16325412 | 0.86 | MDM2 (0.52) | KMT2ASIRT5SIRT2SIRT1SIRT3 | |
| SCHEMBL13401516 | 0.86 | MDM2 (0.52) | KMT2ASIRT5SIRT2SIRT1SIRT3 | |
| SCHEMBL26015705 | 0.86 | TLR2 (0.46) | SIRT5SIRT2SIRT1SIRT3TLR2 | |
| SCHEMBL13196227 | 0.85 | TLR2 (0.45) | KMT2ASIRT5SIRT2SIRT1SIRT3 | |
| SCHEMBL29371674 | 0.85 | TLR2 (0.45) | KMT2ASIRT5SIRT2SIRT1SIRT3 | |
| SCHEMBL13311052 | 0.85 | TLR2 (0.45) | KMT2ASIRT5SIRT2SIRT1SIRT3 | |
| SCHEMBL10078346 | 0.85 | KMT2A (0.50) | KMT2ATLR2 | |
| SCHEMBL16093051 | 0.85 | KMT2A (0.50) | KMT2ATLR2 | |
| SCHEMBL25358347 | 0.84 | KMT2A (0.57) | KMT2ATLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1718340-B1 | NEW EFFECTOR CONJUGATES, PROCESS FOR THEIR PRODUCTION AND THEIR PHARMACEUTICAL USE | BAYER SCHERING PHARMA AG (DE) | 2007-11-21 | — | — | EP | disclosed |
| EP-1718340-A2 | NEW EFFECTOR CONJUGATES, PROCESS FOR THEIR PRODUCTION AND THEIR PHARMACEUTICAL USE | Schering AG (DE) | 2006-11-08 | — | — | EP | disclosed |
| US-20050234247-A1 | New effector conjugates, process for their production and their pharmaceutical use | SCHERING AG (DE) | 2005-10-20 | — | — | US | disclosed |
| WO-2005074901-A2 | NEW EFFECTOR CONJUGATES, PROCESS FOR THEIR PRODUCTION AND THEIR PHARMACEUTICAL USE | SCHERING AG (DE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234247-A1 | New effector conjugates, process for their production and their pharmaceutical use | EPOR, TIE1, TEK | KMT2A 3816/4885SIRT5 3881/4885SIRT2 4181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.